Literature DB >> 20861457

Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development.

Florence Schaffner1, Henri H Versteeg, Anja Schillert, Naho Yokota, Lars C Petersen, Barbara M Mueller, Wolfram Ruf.   

Abstract

Constitutive expression of tissue factor (TF) by cancer cells triggers local activation of the coagulation cascade and promotes breast cancer progression through cell signaling involving protease activated receptor (PAR)2. In human breast cancer, TF and PAR2 are up-regulated and TF cytoplasmic domain phosphorylation is correlated with relapse. Here we show that cancer cell PAR2 signaling promotes angiogenesis independent of PAR2 phosphorylation at the recognized β-arrestin recruitment site. Similar to PAR2(-/-) mice, TF cytoplasmic domain-deleted (TF(ΔCT)) mice have delayed spontaneous breast cancer development in the polyoma middle T model. Simultaneous deletion of PAR2 in TF(ΔCT) mice did not further delay tumor appearance, consistent with overlapping roles of TF and PAR2 in promoting the angiogenic switch in early stages of breast cancer. In advanced carcinomas, tumor-associated macrophages were reduced in TF(ΔCT) and TF(ΔCT)/PAR2(-/-) mice, and increased tumor vessel diameters of TF(ΔCT) mice were partially reversed by PAR2-deficiency, indicating that the TF cytoplasmic domain has additional roles that are interdependent with PAR2 signaling in regulating host angiogenic responses. These experiments demonstrate a crosstalk of tumor cell TF cytoplasmic domain and PAR2 signaling and provide a possible mechanism for the close correlation between TF phosphorylation and cancer recurrence of TF and PAR2-positive clinical breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861457      PMCID: PMC3031395          DOI: 10.1182/blood-2010-06-289314

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells.

Authors:  Dionne R Morris; Yu Ding; Tiffany K Ricks; Anuradha Gullapalli; Breann L Wolfe; JoAnn Trejo
Journal:  Cancer Res       Date:  2006-01-01       Impact factor: 12.701

2.  Proangiogenic effects of protease-activated receptor 2 are tumor necrosis factor-alpha and consecutively Tie2 dependent.

Authors:  Tang Zhu; Florian Sennlaub; Martin Hervé Beauchamp; Li Fan; Jean Sebastian Joyal; Daniella Checchin; Satra Nim; Pierre Lachapelle; Mirna Sirinyan; Xin Hou; Michela Bossolasco; Georges-Etienne Rivard; Nikolaus Heveker; Sylvain Chemtob
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-01-26       Impact factor: 8.311

3.  Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling.

Authors:  Matthias Riewald; Wolfram Ruf
Journal:  J Biol Chem       Date:  2005-03-15       Impact factor: 5.157

4.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.

Authors:  K Abe; M Shoji; J Chen; A Bierhaus; I Danave; C Micko; K Casper; D L Dillehay; P P Nawroth; F R Rickles
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

5.  Characterization of recombinant murine factor VIIa and recombinant murine tissue factor: a human-murine species compatibility study.

Authors:  Lars C Petersen; Peder L Nørby; Sven Branner; Brit B Sørensen; Torben Elm; Henning R Stennicke; Egon Persson; Søren E Bjørn
Journal:  Thromb Res       Date:  2004-12-07       Impact factor: 3.944

6.  Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.

Authors:  B M Mueller; W Ruf
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

7.  Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2.

Authors:  Lan Ge; Sudha K Shenoy; Robert J Lefkowitz; Kathryn DeFea
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

8.  Thrombin receptor overexpression in malignant and physiological invasion processes.

Authors:  S Even-Ram; B Uziely; P Cohen; S Grisaru-Granovsky; M Maoz; Y Ginzburg; R Reich; I Vlodavsky; R Bar-Shavit
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

9.  Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation.

Authors:  M E Bromberg; W H Konigsberg; J F Madison; A Pawashe; A Garen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

10.  Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Farshid Noorbakhsh; Shigeki Tsutsui; Nathalie Vergnolle; Leonie A Boven; Neda Shariat; Mohammed Vodjgani; Kenneth G Warren; Patricia Andrade-Gordon; Morley D Hollenberg; Christopher Power
Journal:  J Exp Med       Date:  2006-02-13       Impact factor: 14.307

View more
  47 in total

1.  Tissue factor and PAR1 promote microbiota-induced intestinal vascular remodelling.

Authors:  Christoph Reinhardt; Mattias Bergentall; Thomas U Greiner; Florence Schaffner; Gunnel Ostergren-Lundén; Lars C Petersen; Wolfram Ruf; Fredrik Bäckhed
Journal:  Nature       Date:  2012-03-11       Impact factor: 49.962

Review 2.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

3.  Discovery of Novel Nonpeptidic PAR2 Ligands.

Authors:  Ilona Klösel; Maximilian F Schmidt; Jonas Kaindl; Harald Hübner; Dorothee Weikert; Peter Gmeiner
Journal:  ACS Med Chem Lett       Date:  2020-05-22       Impact factor: 4.345

4.  Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice.

Authors:  N Yokota; A Zarpellon; S Chakrabarty; V Y Bogdanov; A Gruber; F J Castellino; N Mackman; L G Ellies; H Weiler; Z M Ruggeri; W Ruf
Journal:  J Thromb Haemost       Date:  2014-01       Impact factor: 5.824

5.  Protease-activated-receptor-2 affects protease-activated-receptor-1-driven breast cancer.

Authors:  Mohammad Jaber; Miriam Maoz; Arun Kancharla; Daniel Agranovich; Tamar Peretz; Sorina Grisaru-Granovsky; Beatrice Uziely; Rachel Bar-Shavit
Journal:  Cell Mol Life Sci       Date:  2013-11-01       Impact factor: 9.261

Review 6.  Targeting allosteric disulphide bonds in cancer.

Authors:  Philip J Hogg
Journal:  Nat Rev Cancer       Date:  2013-05-10       Impact factor: 60.716

7.  ImmunoPET imaging of tissue factor expression in pancreatic cancer with 89Zr-Df-ALT-836.

Authors:  Reinier Hernandez; Christopher G England; Yunan Yang; Hector F Valdovinos; Bai Liu; Hing C Wong; Todd E Barnhart; Weibo Cai
Journal:  J Control Release       Date:  2017-08-24       Impact factor: 9.776

Review 8.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 9.  Inflammation, obesity, and thrombosis.

Authors:  Fahumiya Samad; Wolfram Ruf
Journal:  Blood       Date:  2013-10-03       Impact factor: 22.113

10.  Myeloid cell-synthesized coagulation factor X dampens antitumor immunity.

Authors:  Claudine Graf; Petra Wilgenbus; Sven Pagel; Jennifer Pott; Federico Marini; Sabine Reyda; Maki Kitano; Stephan Macher-Göppinger; Hartmut Weiler; Wolfram Ruf
Journal:  Sci Immunol       Date:  2019-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.